| 研究課題/領域番号 |
23K14598
|
|---|
| 研究種目 |
若手研究
|
| 配分区分 | 基金 |
|---|
| 審査区分 |
小区分50010:腫瘍生物学関連
|
|---|
| 研究機関 | 長崎大学 |
|---|
研究代表者 |
YAN Chen 長崎大学, 原爆後障害医療研究所, 講師 (70968396)
|
|---|
| 研究期間 (年度) |
2023-04-01 – 2024-03-31
|
| 研究課題ステータス |
中途終了 (2023年度)
|
| 配分額 *注記 |
4,680千円 (直接経費: 3,600千円、間接経費: 1,080千円)
2024年度: 2,600千円 (直接経費: 2,000千円、間接経費: 600千円)
2023年度: 2,080千円 (直接経費: 1,600千円、間接経費: 480千円)
|
|---|
| キーワード | Cancer stem cells / Mitophagy / Cancer |
|---|
| 研究開始時の研究の概要 |
Cancer stem cells (CSCs) are known to associate with therapeutic resistance and cancer relapse. We will investigate the role and mechanism of mitophagy in maintaining the biological characteristics of CSCs. Our study will provide new insight into mechanism on the biological characteristics of CSCs.
|
| 研究実績の概要 |
To investigate the potential role of mitophagy in maintaining the biological characteristics of cancer stem cells, human colorectal cancer cells (HCT116) were used in experiments. We found that Mdivi-1, a pharmacological mitophagy inhibitor, slightly decreased the clonogenic formation ability of HCT116 cells. Interestingly, doxorubicin treatment of HCT116 cells for 7 days upregulated several mitophagy-related genes and increased mitophagy activity, but inversely decreased the expression of cancer stem cell markers (Sox2 and c-myc). Further studies are warranted to elucidate the precise role and relevant mechanism of mitophagy in cancer stem cells.
|
